BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

enGene, Inc. Completes US$6.4M Series A Financing


3/17/2008 7:23:11 AM

VANCOUVER, BRITISH COLUMBIA--(MARKET WIRE)--Mar 17, 2008 -- enGene Inc., a privately held biotechnology company developing an innovative approach for the treatment of diabetes called GEMS(TM)-Insulin, announced today it has raised US$6.4 million in a Series A financing, consisting of new investment and conversion of an existing convertible note financing. The financing was led by Saad Investments Company Ltd. and included Masa Life Science Ventures LP (MLSV) of Washington, DC and private investors.

"This significant, internationally syndicated financing will provide us with sufficient funds to achieve several near-term, value-driving milestone in the development of the GEMS(TM)-Insulin program, which will then lay the foundation for a Series B financing in the second half of 2008," said Eric A. Adams, President and CEO of enGene.

"enGene's management and scientific teams have diligently invested their resources to significantly advance the unique and promising GEMS(TM)-Insulin product," commented A. Sinclair Dunlop of MLSV, who joined the enGene Board of Directors as the representative of the Series A investors. "This, combined with the potential of the Company's platform technology across several diseases, makes enGene a very exciting addition to our portfolio."

More about enGene Inc. and GEMS(TM) for Diabetes

enGene's technology, Gut Endocrine-cell Modification System (GEMS(TM)), utilizes the therapeutic protein production capacity of existing, normal, healthy cells in a small, targeted area of the duodenum by delivering a gene construct in a novel non-viral vector. For GEMS(TM)-Insulin, this means enabling the patients' own cells to produce insulin in a regulated, meal-dependant fashion resulting in physiologic control of blood glucose levels. Other potential applications for GEMS(TM) include inflammatory bowel disease, obesity, anemia, and hemophilia.

Additional information about the Company, as well as scientific information related to the above presentation, is available at www.engeneinc.com.

Contact: Contacts: enGene Inc. Eric A. Adams CEO (604) 221-4362 x230 (604) 221-4369 (FAX) Website: http://www.engeneinc.com

Source: enGene Inc.

Read at BioSpace.com

   
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES